PSMA-PET imaging avidity
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-PSMA-PET |
|---|---|
| Type | Biomarker |
| Aliases | ПСМА-ПЕТ-авідність |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | None declared |
Biomarker Facts
| Biomarker type | protein_expression_imaging |
|---|---|
| Measurement | MethodGa-68-PSMA-11 OR F-18-PSMA-1007 PET/CT Unitsqualitative (positive / negative) per VISION criteria |
| Related biomarkers | None declared |
Notes
Drives Lu-PSMA selection. Requires nuclear medicine infrastructure. In Ukraine PSMA-PET availability concentrated in 2-3 academic centers (Kyiv, Dnipro). Access barrier.
Used By
Indications
IND-PROSTATE-MCRPC-2L-LU-PSMA- IND-PROSTATE-MCRPC-2L-LU-PSMA
Questionnaires
QUEST-PROSTATE-1L-STUB- Prostate adenocarcinoma — first line
Tests
TEST-PSMA-PET- PSMA-PET/CT (Ga-68 or F-18)